Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model

Cancer Research

Volumn 68, Issue 16, 2008, Pages 6822-6830

  Raina, Komal ^a   Rajamanickam, Subapriya ^a   Singh, Rana P ^a,c   Deep, Gagan ^a   Chittezhath, Manesh ^a   Agarwal, Rajesh ^a,b,d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; SILIBININ; TRANSCRIPTION FACTOR SNAIL; VASCULOTROPIN RECEPTOR 2; ANTIOXIDANT; CELL CYCLE PROTEIN; SILYMARIN; TUMOR MARKER; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DRUG EFFICACY; FEMALE; MALE; METASTASIS INHIBITION; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; ADENOCARCINOMA; ANIMAL; APOPTOSIS; BODY WEIGHT; C57BL MOUSE; CANCER STAGING; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; HUMAN; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SILYBUM MARIANUM; TRANSGENIC MOUSE; VASCULARIZATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; BODY WEIGHT; CELL CYCLE PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MILK THISTLE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SILYMARIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53049106036     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1332     Document Type: Article

References (31)

1. Stewart AB, Lwaleed BA, Douglas DA, Birch BR. Current drug therapy for prostate cancer: an overview. Curr Med Chem Anti-Canc Agents 2005;5:603-12.
2. Brand TC, Canby-Hagino ED, Pratap Kumar A, et al. Chemoprevention of prostate cancer. Hematol Oncol Clin North Am 2006;20:831-43.
3. Klein EA. Chemoprevention of prostate cancer. Annu Rev Med 2006;57:49-63.
4. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006;13:751-78.
5. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol 2007;178:S9-13.
6. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82.
7. Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 2007;67:5976-82.
8. Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006; 45:436-42.
9. Gingrich JR, Barrios RJ, Kattan MW, et al. Androgenindependent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
10. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56:4096-102.
11. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996;24:502-4.
12. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
13. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
14. Greenberg NM, DeMayo FJ, Sheppard PC, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-9.
15. Raina K, Blouin MJ, Singh RP, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007;67:11083-91.
16. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003;12:933-9.
17. Gu M, Dhanalakshmi S, Mohan S, Singh RP, Agarwal R. Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis 2005;26:1404-13.
18. Bhat TA, Singh RP. Tumor angiogenesis - A potential target in cancer chemoprevention. Food Chem Toxicol 2008;46:1334-45. Epub 2007 Aug. 29.
19. Ozawa MG, Yao VJ, Chanthery YH, et al. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 2005;104:2104-15.
20. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
21. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
22. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A 1998;95:15809-14.
23. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor lα in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
24. Singh RP, Agarwal R. Inducible nitric oxide synthasevascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents. Curr Cancer Drug Targets 2007;7:475-83.
25. Bok RA, Hansell EJ, Nguyen TP, et al. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis 2003;6:272-80.
26. Przybylo JA, Radisky DC. Matrix metalloproteinaseinduced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol 2007;39:1082-8.
27. Radisky D, Muschler J, Bissell MJ. Order and disorder: the role of extracellular matrix in epithelial cancer. Cancer Invest 2002;20:139-53.
28. Turner HE, Harris AL, Melmed S, Wass JA. Angiogenesis in endocrine tumors. Endocr Rev 2003;24:600-32.
29. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 2007;67:5789-97.
30. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 2005;118:4325-6.
31. Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene 2007;26:1862-74.